Safety, Tolerability and Effect of Laquinimod in Subjects With Relapsing Multiple Sclerosis
Study Title
- A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis
Teva Identifier
- MS-LAQ-302E | 2009-015815-42
ClinicalTrials.gov Identifier
- NCT01047319
Study Status
- Terminated
Trial Condition(s)
- Relapsing Multiple Sclerosis
Interventions
- Drug: Laquinimod
Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
Gender
- Female, Male
Age Range
- Child, Adult, Older Adult
Trial Duration
- May 27, 2010 - June 30, 2017
Phase
- Phase 3
Study Type
Interventional
